Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959016 | 0.94 | MEN1 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL4814264 | 0.92 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL379160 | 0.92 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL7393652 | 0.92 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL3970912 | 0.92 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL15011579 | 0.90 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| Bicarbonate SCHEMBL4357688 | 0.90 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL3795583 | 0.87 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL16611411 | 0.87 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL8010989 | 0.86 | SMN1; SMN2 (0.68) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| EP-3199530-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | Changzhou Yinsheng Pharmaceutical Co., Ltd. (CN) | 2017-08-02 | — | — | EP | disclosed |
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| EP-0704439-B1 | NOVEL INTERMEDIATE FOR SYNTHETIC USE AND PROCESS FOR PRODUCING AMINOPIPERAZINE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-5708172-A | Intermediates for synthetic use and processes for producing aminopiperazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0704439-A1 | NOVEL INTERMEDIATE FOR SYNTHETIC USE AND PROCESS FOR PRODUCING AMINOPIPERAZINE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | MEN1 3731/4885KMT2A 1796/4885NPSR1 4721/4885 |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | GTF3C4, BRD4, CUL4B | MEN1 4487/4885KMT2A 2117/4885NPSR1 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.